Armstrong Advisory Group’s Sanofi SNY Stock Holding History

Armstrong Advisory Group’s Portfolio SNY Stock Details SNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-23	Closed	-$982	–	1087
2026 Q2	$982	Hold	23	–	–	﹤0.01%	946
2026 Q1	$1.11K	Hold	23	–	–	﹤0.01%	915
2025 Q4	$1.12K	Hold	23	–	–	﹤0.01%	909
2025 Q3	$1.09K	Hold	23	–	–	﹤0.01%	893
2025 Q2	$1.11K	Buy	+23	New	+$1.18K	﹤0.01%	871

Other funds holding SNY

Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Mondrian Investment Partners London, United Kingdom $5.39B AUM 14.53% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Boston Partners Boston, Massachusetts $111B AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return

Armstrong Advisory Group's SNY Position: Q3 2026 in Review

Armstrong Advisory Group sold out of Sanofi (SNY) in Q3 2026, closing a stake of 23 shares — an estimated $982 sold.

Armstrong Advisory Group first reported a position in SNY in Q2 2025 and held it in 5 quarters. The position peaked at $1.12K in Q4 2025. 577 funds tracked by Wall St. Rank hold SNY as of Q3 2026.

Armstrong Advisory Group reported no remaining Sanofi position as of Q3 2026 after selling out during the quarter.
Armstrong Advisory Group sold 23 Sanofi shares in Q3 2026, an estimated $982.
Armstrong Advisory Group first reported a position in Sanofi in Q2 2025 and held it in 5 quarters.
Armstrong Advisory Group's Sanofi position peaked at $1.12K in Q4 2025.
577 funds tracked by Wall St. Rank held Sanofi as of Q3 2026.

Based on Armstrong Advisory Group's 13F filing for Q3 2026, filed 9 Oct 2026.